“…Multiple studies of HPgV-1 prevalence in hepatitis/liver disease patients have been reported, including in China, India, Indonesia, Iran, Japan, Lebanon, Mongolia, Myanmar, Nepal, Pakistan, Qatar, Saudi Arabia, Singapore, South Korea, Taiwan, Thailand, Turkey, the United Arab Emirates and Vietnam. [77][78][79][80][81][82][84][85][86][87][88][89][90][91][92][93][94][95][96][97][98][99]101,107,112, HPgV-1 prevalence rates above 10% were observed in China, 90,98,99,107,118,119,124,135,[142][143][144] India, 80,85,92,117,126 Indonesia, 93 Iran, 123 Japan, 66,125,131,[138][139]…”